Table of Content

1. Introduction



2. Research Methodology



3. Executive Summary



4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Exploring the Disease – Background and Key Insights
5.1 Introduction
5.2 Causes
5.3 Classificationof Epilepsies

5.3.1 West Syndrome
5.3.2 Dravet syndrome
5.3.3 Lennox–Gastaut syndrome
5.3.4 Landau–Kleffner syndrome
5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
5.3.6 CDKL5 deficiency disorder (CDD)

5.4 Risk Factors
5.5 Pathophysiology
5.6 Diagnosis

5.6.1 Diagnostic Guidelines

5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)
5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)
5.6.1.3 The French National Authority for Health (HAS): 2020
5.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)

5.7 Treatment

5.7.1 Antiepileptic Medications (AEDs)
5.7.2 Receptor Blockers
5.7.3 Others
5.7.4 Diet Therapy
5.7.5 Surgery

5.7.5.1 Phase I Evaluation (Noninvasive Tests)
5.7.5.2 Phase II Evaluation (Invasive Mon)

5.7.6 Treatment Algorithm for Medical Condition
5.7.7 Treatment Guidelines

5.7.7.1 American Epilepsy Society
5.7.7.2 American Family Physician – Epilepsy Treatment Options (2017)
5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines
5.7.7.4 NICE Guidelines: (2022)

5.7.8 Living and Coping with Epilepsy


6. Global Epilepsy Drugs Market


7. Market Share
7.1 By Drugs Category
7.2 By Seizure types
7.3 By Distribution Channels
7.4 By Countries


8. Drugs Category
8.1 First Generation Drugs
8.2 Second Generation Drugs
8.3 Third Generation Drugs


9. Seizure Types
9.1 Focal Seizures
9.2 Generalized Seizures
9.3 Non-Epileptic Seizures


10. Distribution Channels
10.1 Hospital Pharmacies
10.2 Drug Stores and Retail Pharmacies
10.3 Online Providers


11. Countries
11.1 North America

11.1.1 United States
11.1.2 Canada

11.2 Europe

11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherland
11.2.8 Turkey

11.3 Asia Pacific

11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand

11.4 Latin America

11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina

11.5 Middle East & Africa

11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa

11.6 Rest of the World


12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes


13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat


14. Analysis of Marketed Medications/Drugs
14.1 Key Players

14.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) – Jazz Pharmaceuticals

14.2.1 Description of Drugs
14.2.2 Regulatory Milestones
14.2.3 Clinical Development Process
14.2.4 Safety and Efficacy

14.3 XCOPRI/ONTOZRY(cenobamate) – SK Biopharmaceutical/ Pharma/Ono Pharmaceutical

14.3.1 Description of Drugs
14.3.2 Regulatory Milestones
14.3.3 Clinical Development Process
14.3.4 Safety and Efficacy

14.4 FINTEPLA (fenfluramine) – UCB/Nippon Shinyaku

14.4.1 Description of Drugs
14.4.2 Regulatory Milestones
14.4.3 Clinical Development Process
14.4.4 Safety and Efficacy

14.5 NAYZILAM (midazolam) nasal spray – UCB Pharma

14.5.1 Description of Drugs
14.5.2 Regulatory Milestones
14.5.3 Clinical Development Process
14.5.4 Safety and Efficacy

14.6 VALTOCO (diazepam nasal spray) – Neurelis/Aculys Pharma

14.6.1 Description of Drugs
14.6.2 Regulatory Milestones
14.6.3 Clinical Development Process
14.6.4 Safety and Efficacy

14.7 ZTALMY (ganaxolone) – Marinus Pharmaceuticals/Ovid Therapeutics/Orion

14.7.1 Description of Drugs
14.7.2 Regulatory Milestones
14.7.3 Clinical Development Process
14.7.4 Safety and Efficacy

14.8 BRIVIACT/NUBRIVEO (brivaracetam) – UCB Pharma

14.8.1 Description of Drugs
14.8.2 Regulatory Milestones
14.8.3 Clinical Development Process
14.8.4 Safety and Efficacy

14.9 FYCOMPA (perampanel) – Eisai/Catalyst Pharmaceutical

14.9.1 Description of Drugs
14.9.2 Regulatory Milestones
14.9.3 Clinical Development Process
14.9.4 Safety and Efficacy

14.10 OXTELLAR XR (oxcarbazepine) – Supernus Pharmaceuticals

14.10.1 Description of Drugs
14.10.2 Regulatory Milestones
14.10.3 Clinical Development Process
14.10.4 Safety and Efficacy

14.11 VIMPAT (lacosamide) – UCB Pharma/Daiichi Sankyo

14.11.1 Description of Drugs
14.11.2 Regulatory Milestones
14.11.3 Clinical Development Process
14.11.4 Safety and Efficacy


15. Analysis of Emerging Drugs
15.1 Key Cross Competition

15.2 XEN1101 – Xenon Pharmaceuticals

15.2.1 Description of Drug
15.2.2 Clinical Research & Development
15.2.3 Safety and efficacy

15.3 LIBERVANT (diazepam buccal film) – Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

15.3.1 Description of Drug
15.3.2 Clinical Research & Development
15.3.3 Safety and efficacy

15.4 Soticlestat (TAK-935) – Takeda/Ovid Therapeutics

15.4.1 Description of Drug
15.4.2 Clinical Research & Development
15.4.3 Safety and efficacy

15.5 COMFYDE (carisbamate) – SK Biopharmaceuticals (SK Life Science)

15.5.1 Description of Drug
15.5.2 Clinical Research & Development
15.5.3 Safety and efficacy

15.6 BHV-7000 (KB-3061) – Biohaven Pharmaceuticals/Knopp Biosciences

15.6.1 Description of Drug
15.6.2 Clinical Research & Development
15.6.3 Safety and efficacy

15.7 STACCATO alprazolam (benzodiazepine) – UCB Pharma/Alexza Pharmaceuticals

15.7.1 Description of Drug
15.7.2 Clinical Research & Development
15.7.3 Safety and efficacy

15.8 NBI-827104 (ACT-709478) – Neurocrine Biosciences/Idorsia Pharmaceuticals

15.8.1 Description of Drug
15.8.2 Clinical Research & Development
15.8.3 Safety and efficacy

15.9 Ivermectin (EQU-001) – Equilibre Biopharmaceuticals

15.9.1 Description of Drug
15.9.2 Clinical Research & Development
15.9.3 Safety and efficacy

16. Regulations and Reimbursement Policies


17. Key Players Analysis
17.1 Eisai Co., Ltd.

17.1.1 Overview
17.1.2 Recent Development
17.1.3 Revenue Analysis

17.2 UCB Inc.

17.2.1 Overview
17.2.2 Recent Development
17.2.3 Revenue Analysis

17.3 H. Lundbeck A/S

17.3.1 Overview
17.3.2 Recent Development
17.3.3 Revenue Analysis

17.4 GW Pharmaceuticals Plc.

17.4.1 Overview
17.4.2 Recent Development
17.4.3 Revenue Analysis

17.5 Abbott Laboratories

17.5.1 Overview
17.5.2 Recent Development
17.5.3 Revenue Analysis

17.6 Alkem Laboratories Limited

17.6.1 Overview
17.6.2 Recent Development
17.6.3 Revenue Analysis

17.7 Bausch Health Companies Inc.

17.7.1 Overview
17.7.2 Recent Development
17.7.3 Revenue Analysis

17.8 GSK plc

17.8.1 Overview
17.8.2 Recent Development
17.8.3 Revenue Analysis

17.9 Novartis AG

17.9.1 Overview
17.9.2 Recent Development
17.9.3 Revenue Analysis

17.10 Pfizer Inc

17.10.1 Overview
17.10.2 Recent Development
17.10.3 Revenue Analysis



List of Figures

0

List of Tables

0